Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0033 USD | 0.00% | 0.00% | 0.00% |
Valuation
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 33.18 | 37.82 | 1.5 | 2.756 | 0.8812 | 0.1024 |
Enterprise Value (EV) 1 | 33.51 | 37.78 | 1.971 | 3.317 | 1.827 | 0.8939 |
P/E ratio | -5.5 x | -1.5 x | -0.6 x | -1.34 x | -0.57 x | -0.25 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -45 x | -1.56 x | -1.52 x | -3.59 x | -1.05 x | -1.81 x |
EV / FCF | 282 x | 4.15 x | 7.61 x | 21.2 x | -33.8 x | -12.8 x |
FCF Yield | 0.36% | 24.1% | 13.1% | 4.72% | -2.96% | -7.83% |
Price to Book | 18.8 x | -50.4 x | -0.84 x | -1.26 x | -0.28 x | -0.03 x |
Nbr of stocks (in thousands) | 11,849 | 14,434 | 21,462 | 25,754 | 33,892 | 34,146 |
Reference price 2 | 2.800 | 2.620 | 0.0699 | 0.1070 | 0.0260 | 0.003000 |
Announcement Date | 18-11-27 | 19-11-14 | 20-11-04 | 22-03-31 | 22-11-25 | 24-02-26 |
Income Statement Evolution (Annual data)
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -0.7445 | -24.23 | -1.298 | -0.9236 | -1.734 | -0.4925 |
EBIT 1 | -0.7699 | -24.26 | -1.318 | -0.94 | -1.746 | -0.4939 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.139 | -23.31 | -1.925 | -1.885 | -1.519 | -0.387 |
Net income 1 | -6.139 | -23.31 | -1.925 | -1.885 | -1.519 | -0.387 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.5093 | -1.742 | -0.1163 | -0.0797 | -0.0457 | -0.0118 |
Free Cash Flow 1 | 0.119 | 9.096 | 0.259 | 0.1567 | -0.054 | -0.07 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 18-11-27 | 19-11-14 | 20-11-04 | 22-03-31 | 22-11-25 | 24-02-26 |
Balance Sheet Analysis
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 0.33 | - | 0.47 | 0.56 | 0.95 | 0.79 |
Net Cash position 1 | - | 0.04 | - | - | - | - |
Leverage (Debt/EBITDA) | -0.447 x | - | -0.3624 x | -0.608 x | -0.5454 x | -1.607 x |
Free Cash Flow 1 | 0.12 | 9.1 | 0.26 | 0.16 | -0.05 | -0.07 |
ROE (net income / shareholders' equity) | -705% | -3,921% | 152% | 89.3% | 54.4% | 12.1% |
ROA (Net income/ Total Assets) | -35.5% | -998% | -272% | -208% | -318% | -281% |
Assets 1 | 17.31 | 2.336 | 0.7072 | 0.9073 | 0.4781 | 0.1378 |
Book Value Per Share 2 | 0.1500 | -0.0500 | -0.0800 | -0.0800 | -0.0900 | -0.1000 |
Cash Flow per Share 2 | 0 | 0.0200 | 0 | 0.0100 | - | - |
Capex 1 | 0 | 0 | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 18-11-27 | 19-11-14 | 20-11-04 | 22-03-31 | 22-11-25 | 24-02-26 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 133K | |
-8.07% | 9.27B | |
+27.40% | 4.95B | |
+6.31% | 4.26B | |
+46.07% | 3.18B | |
+83.87% | 2.3B | |
-9.38% | 1.3B | |
-6.79% | 672M | |
+9.79% | 566M | |
+39.30% | 560M |
- Stock Market
- Equities
- THCT Stock
- Financials THC Therapeutics, Inc.